Up-regulating telomerase and tumor suppressors: Focusing on anti-aging interventions at the population level

Aging and Disease

Volumn 5, Issue 1, 2014, Pages 17-26

  Hartwig, Fernando Pires ^a   Bertoldi, Daniel ^a   Larangeira, Martin ^a   Wagner, Mônica Silveira ^b  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^b NONE

Author keywords

Aging; Levels of disease prevention; Population level interventions; Telomerase; Tumor suppression

Indexed keywords

MUS;

EID: 84916897238     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: 10.14336/AD.2014.050017     Document Type: Article

References (80)

1. Beaglehole R, Bonita R, Alleyne G, Horton R, Li L, Lincoln P, et al. (2011). UN High-Level Meeting on Non-Communicable Diseases: addressing four questions. Lancet, 378:449-455.
2. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013). The hallmarks of aging. Cell, 153:1194-1217.
3. Abbott A (2009). Chromosome protection scoops Nobel. Nature, 461:706-707.
4. de Lange T (2005). Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev, 19:2100-2110.
5. Palm W, de Lange T. (2008). How shelterin protects mammalian telomeres. Annu Rev Genet, 42:301-334.
6. Olovnikov AM (1973). A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol, 41:181-190.
7. Richter T, von Zglinicki T. (2007). A continuous correlation between oxidative stress and telomere shortening in fibroblasts. Exp Gerontol, 42:1039-1042.
8. Greider CW, Blackburn EH (1985). Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell, 43:405-413.
9. Greider CW, Blackburn EH (1987). The telomere terminal transferase of Tetrahymena is aribonucleoprotein enzyme with two kinds of primer specificity. Cell, 51:887-898.
10. Flores I, Benetti R, Blasco MA (2006). Telomerase regulation and stem cell behaviour. Curr Opin Cell Biol, 18:254-260.
11. Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. (2011). Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature, 479:232-236.
12. Armanios M, Blackburn EH (2012). The telomere syndromes. Nat Rev Genet, 13:693-704.
13. Feldser DM, Hackett JA, Greider CW (2003). Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer, 3:623-627.
14. Shay JW, Bacchetti S (1997). A survey of telomerase activity in human cancer. Eur J Cancer, 33:787-791.
15. Belair CD, Yeager TR, Lopez PM, Reznikoff CA (1997). Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci U S A, 94:13677-13682.
16. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144:646-674.
17. Hartwig FP, Collares T (2013). Telomere dysfunction and tumor suppression responses in dyskeratosis congenita: balancing cancer and tissue renewal impairment. Ageing Res Rev, 12:642-652.
18. Good PI (1977). Astochastic model for in vitro ageing II. A theory of marginotomy. J Theor Biol, 64:261-275.
19. Harley CB, Futcher AB, Greider CW (1990). Telomeres shorten during ageing of human fibroblasts. Nature, 345:458-460.
20. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, et al. (1992). Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A, 89:10114-10118.
21. Wright WE, Shay JW (1992). The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol, 27:383-389.
22. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, et al. (1997). Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet, 17:498-502.
23. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science, 279:349-352.
24. Vaziri H, Benchimol S (1998). Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol, 8:279-282.
25. Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, et al. (2011). Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature, 469:102-106.
26. Tomas-Loba A, Flores I, Fernandez-Marcos PJ, Cayuela ML, Maraver A, Tejera A, et al. (2008). Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell, 135:609-622.
27. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, et al. (2007). Delayed ageing through damage protection by the Arf/p53 pathway. Nature, 448:375-379.
28. He S, Nakada D, Morrison SJ (2009). Mechanisms of stem cell self-renewal. Annu Rev Cell Dev Biol, 25:377-406.
29. Donate LE, Blasco MA (2011). Telomeres in cancer and ageing. Philos Trans R Soc Lond B Biol Sci, 366:76-84.
30. Wang XB, Zhu L, Huang J, Yin YG, Kong XQ, Rong QF, et al. (2011). Resveratrol-induced augmentation of telomerase activity delays senescence of endothelial progenitor cells. Chin Med J (Engl), 124:4310-4315.
31. Pearce VP, Sherrell J, Lou Z, Kopelovich L, Wright WE, Shay JW (2008). Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene, 27:2365-2374.
32. Minamino T, Komuro I (2008). Vascular aging: insights from studies on cellular senescence, stem cell aging, and progeroid syndromes. Nat Clin Pract Cardiovasc Med, 5:637-648.
33. Hartwig FP, Nedel F, Collares TV, Tarquinio SB, Nor JE, Demarco FF (2012). Telomeres and tissue engineering: the potential roles of TERT in VEGF-mediated angiogenesis. Stem Cell Rev, 8:1275-1281.
34. da Luz PL, Tanaka L, Brum PC, Dourado PM, Favarato D, Krieger JE, et al. (2012). Red wine and equivalent oral pharmacological doses of resveratrol delay vascular aging but do not extend life span in rats. Atherosclerosis, 224:136-142.
35. Zajkowicz A, Krzesniak M, Matuszczyk I, Glowala-Kosinska M, Butkiewicz D, Rusin M (2013). Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol. Mol Biol Rep, 40:5013-5026.
36. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444:337-342.
37. Masoro EJ (2001). Dietary restriction: current status. Aging (Milano), 13:261-262.
38. Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R (2012). Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev, 11:390-398.
39. Shanley DP, Kirkwood TB (2006). Caloric restriction does not enhance longevity in all species and is unlikely to do so in humans. Biogerontology, 7:165-168.
40. Liao CY, Rikke BA, Johnson TE, Diaz V, Nelson JF (2010). Genetic variation in the murine lifespan response to dietary restriction: from life extension to life shortening. Aging Cell, 9:92-95.
41. Weindruch R, Walford RL (1982). Dietary restriction in mice beginning at 1 year of age: effect on life-span and spontaneous cancer incidence. Science, 215:1415-1418.
42. Weindruch R, Walford RL, Fligiel S, Guthrie D (1986). The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J Nutr, 116:641-654.
43. Turturro A, Witt WW, Lewis S, Hass BS, Lipman RD, Hart RW (1999). Growth curves and survival characteristics of the animals used in the Biomarkers of Aging Program. J Gerontol A Biol Sci Med Sci, 54:B492-501.
44. Dhahbi JM, Kim HJ, Mote PL, Beaver RJ, Spindler SR (2004). Temporal linkage between the phenotypic and genomic responses to caloric restriction. Proc Natl Acad Sci U S A, 101:5524-5529.
45. Chou MW, Mikhailova MV, Nichols J, Poirier LA, Warbritton A, Beland FA (2000). Interactive effects of methyl-deficiency and dietary restriction on liver cell proliferation and telomerase activity in Fischer 344 rats pretreated with aflatoxin B(1). Cancer Lett, 152:53-61.
46. Bedard LL, Massey TE (2006). Aflatoxin B1-induced DNA damage and its repair. Cancer Lett, 241:174-183.
47. Li Y, Liu L, Tollefsbol TO (2010). Glucose restriction can extend normal cell lifespan and impair precancerous cell growth through epigenetic control of hTERT and p16 expression. FASEB J, 24:1442-1453.
48. Wang C, Maddick M, Miwa S, Jurk D, Czapiewski R, Saretzki G, et al. (2010). Adult-onset, short-term dietary restriction reduces cell senescence in mice. Aging (Albany NY), 2:555-566.
49. Vera E, Bernardes de Jesus B, Foronda M, Flores JM, Blasco MA. (2013). Telomerase reverse transcriptase synergizes with calorie restriction to increase health span and extend mouse longevity. PLoS One, 8:e53760.
50. Koubova J, Guarente L (2003). How does calorie restriction work? Genes Dev, 17:313-321.
51. Bordone L, Guarente L (2005). Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol, 6:298-305.
52. Beltrami AP, Cesselli D, Beltrami CA (2012). Stem cell senescence and regenerative paradigms. Clin Pharmacol Ther, 91:21-29.
53. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT (2012). Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet, 380:219-229.
54. Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, et al. (2003). Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol, 95:1851-1860.
55. Glass D, Roubenoff R (2010). Recent advances in the biology and therapy of muscle wasting. Ann N Y Acad Sci, 1211:25-36.
56. Marcell TJ (2003). Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci, 58:M911-916.
57. Werner C, Hanhoun M, Widmann T, Kazakov A, Semenov A, Poss J, et al. (2008). Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J Am Coll Cardiol, 52:470-482.
58. Ludlow AT, Witkowski S, Marshall MR, Wang J, Lima LC, Guth LM, et al. (2012). Chronic exercise modifies age-related telomere dynamics in a tissue-specific fashion. J Gerontol A Biol Sci Med Sci, 67:911-926.
59. Ho RT, Chan JS, Wang CW, Lau BW, So KF, Yuen LP, et al. (2012). A randomized controlled trial of qigong exercise on fatigue symptoms, functioning, and telomerase activity in persons with chronic fatigue or chronic fatigue syndrome. Ann Behav Med, 44:160-170.
60. Gibala MJ, McGee SL, Garnham AP, Howlett KF, Snow RJ, Hargreaves M (2009). Brief intense interval exercise activates AMPK and p38 MAPK signaling and increases the expression of PGC-1alpha in human skeletal muscle. J Appl Physiol, 106:929-934.
61. Cuadrado A, Nebreda AR (2010). Mechanisms and functions of p38 MAPK signalling. Biochem J, 429:403-417.
62. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, et al. (2008). Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem, 283:3979-3987.
63. Bartlett JD, Hwa Joo C, Jeong TS, Louhelainen J, Cochran AJ, Gibala MJ, et al. (2012). Matched work high-intensity interval and continuous running induce similar increases in PGC-1alpha mRNA, AMPK, p38, and p53 phosphorylation in human skeletal muscle. J Appl Physiol, 112:1135-1143.
64. Harley CB, Liu W, Blasco M, Vera E, Andrews WH, Briggs LA, et al. (2011). A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res, 14:45-56.
65. Bernardes de Jesus B, Schneeberger K, Vera E, Tejera A, Harley CB, Blasco MA. (2011). The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell, 10:604-621.
66. Harley CB, Liu W, Raffaele JM, Flom PL (2013). A natural product telomerase activator as part of a health maintenance program: Metabolic and cardiovascular response. Rejuvenation Res.
67. Lin PC, Chiou TW, Liu PY, Chen SP, Wang HI, Huang PC, et al. (2012). Food supplement 20070721-GX may increase CD34+ stem cells and telomerase activity. J Biomed Biotechnol, 2012:498051.
68. Le Saux CJ, Davy P, Brampton C, Ahuja SS, Fauce S, Shivshankar P, et al. (2013). A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis. PLoS One, 8:e58423.
69. Zhu J, Lee S, Ho MK, Hu Y, Pang H, Ip FC, et al. (2010). In vitro intestinal absorption and first-pass intestinal and hepatic metabolism of cycloastragenol, a potent small molecule telomerase activator. Drug Metab Pharmacokinet, 25:477-486.
70. Yung LY, Lam WS, Ho MK, Hu Y, Ip FC, Pang H, et al. (2012). Astragaloside IV and cycloastragenol stimulate the phosphorylation of extracellular signal-regulated protein kinase in multiple cell types. Planta Med, 78:115-121.
71. Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, et al. (2013). Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development. J Med Chem.
72. Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, et al. (2013). A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice. J Med Chem.
73. Voltan R, Secchiero P, Ruozi B, Caruso L, Forni F, Palomba M, et al. (2013). Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53(wild-type) JVM-2 but not towards p53(mutated) BJAB leukemic cells. Curr Med Chem, 20:2712-2722.
74. Villalonga-Planells R, Coll-Mulet L, Martinez-Soler F, Castano E, Acebes JJ, Gimenez-Bonafe P, et al. (2011). Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One, 6:e18588.
75. Bonita R, Beaglehole R, Kjellström T (2006). Epidemiology and prevention: chronic noncommunicable diseases. In: Basic Epidemiology. Geneva: WHO Press, 99-114.
76. Schroder CP, Wisman GB, de Jong S, van der Graaf WT, Ruiters MH, Mulder NH, et al. (2001). Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer, 84:1348-1353.
77. Cheung-Ong K, Giaever G, Nislow C (2013). DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol, 20:648-659.
78. Babizhayev MA, Yegorov YE (2011). Smoking and health: association between telomere length and factors impacting on human disease, quality of life and life span in a large population-based cohort under the effect of smoking duration. Fundam Clin Pharmacol, 25:425-442.
79. Babizhayev MA, Savel'yeva EL, Moskvina SN, Yegorov YE (2011). Telomere length is a biomarker of cumulative oxidative stress, biologic age, and an independent predictor of survival and therapeutic treatment requirement associated with smoking behavior. Am J Ther, 18:e209-226.
80. Smith GD, Ebrahim S (2003). 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol, 32:1-22.